Last reviewed · How we verify
vaccine prophylaxis
At a glance
| Generic name | vaccine prophylaxis |
|---|---|
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants (PHASE2)
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (PHASE2)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vaccine prophylaxis CI brief — competitive landscape report
- vaccine prophylaxis updates RSS · CI watch RSS
- Fondazione IRCCS Policlinico San Matteo di Pavia portfolio CI